Skip to content

Study · Animal study (in vivo) · rat · 1982

8 results

Effects of DDAVP and AVP on sodium and water balance in conscious rat.

Gross PA, Anderson RJ

The American journal of physiology1 Nov 1982Cited by 22 (Europe PMC)

PMID7137381 (opens in a new tab)DOI10.1152/ajpregu.1982.243.5.r512 (opens in a new tab)PepBankPUB-07137381
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats receiving hypotonic fluid, chronic DDAVP infusion produced progressive increases in urine flow.

    In plain wordsIn rats receiving hypotonic fluid, urine flow progressively increased during DDAVP infusion.

    Peptide
    Desmopressin
    Outcome
    IncreaseUrine flow
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    Progressive increases in urine flow and decreases in urine osmolality and free water reabsorption occurred in vasopressin-treated animals.
    3 context sentences
    Summary · context
    This decreased hydrosmotic effect was noted with both DDAVP and AVP and could be dissociated from hormonal degradation and urinary prostaglandin E2 excretion.
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats receiving hypotonic fluid, chronic DDAVP infusion produced progressive decreases in urine osmolality.

    In plain wordsIn rats receiving hypotonic fluid, urine concentration progressively decreased during DDAVP infusion.

    Peptide
    Desmopressin
    Outcome
    DecreaseUrine osmolality
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    Progressive increases in urine flow and decreases in urine osmolality and free water reabsorption occurred in vasopressin-treated animals.
    3 context sentences
    Summary · context
    This decreased hydrosmotic effect was noted with both DDAVP and AVP and could be dissociated from hormonal degradation and urinary prostaglandin E2 excretion.
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats receiving hypotonic fluid, chronic DDAVP infusion produced progressive decreases in free water reabsorption.

    In plain wordsIn rats receiving hypotonic fluid, free water reabsorption progressively decreased during DDAVP infusion.

    Peptide
    Desmopressin
    Outcome
    DecreaseFree water reabsorption
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    Progressive increases in urine flow and decreases in urine osmolality and free water reabsorption occurred in vasopressin-treated animals.
    3 context sentences
    Summary · context
    This decreased hydrosmotic effect was noted with both DDAVP and AVP and could be dissociated from hormonal degradation and urinary prostaglandin E2 excretion.
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, the reduced hydrosmotic effect of DDAVP could be dissociated from hormonal degradation and urinary prostaglandin E2 excretion.

    In plain wordsIn rats, the reduced water-retaining effect of DDAVP could be separated from hormone breakdown and urinary prostaglandin E2 excretion.

    Peptide
    Desmopressin
    Outcome
    DecreaseHydrosmotic adaptation
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    This decreased hydrosmotic effect was noted with both DDAVP and AVP and could be dissociated from hormonal degradation and urinary prostaglandin E2 excretion.
    2 context sentences
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats receiving hypotonic fluid and DDAVP, sodium balance remained constant.

    In plain wordsIn rats receiving hypotonic fluid and DDAVP, sodium balance remained constant.

    Peptide
    Desmopressin
    Outcome
    No significant changeSodium balance
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    In DDAVP-treated animals, sodium balance remained constant and hyponatremia resulted from water retention alone.
    2 context sentences
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats receiving hypotonic fluid and DDAVP, hyponatremia resulted from water retention alone.

    In plain wordsIn rats receiving hypotonic fluid and DDAVP, water retention alone lowered blood sodium.

    Peptide
    Desmopressin
    Outcome
    DecreaseHyponatremia mechanism
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    In DDAVP-treated animals, sodium balance remained constant and hyponatremia resulted from water retention alone.
    2 context sentences
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rats, sodium balance differed between DDAVP and AVP treatment independently of water retention magnitude or filtered sodium load.

    In plain wordsIn rats, DDAVP and AVP differed in sodium balance, without differences in water retention or filtered sodium load explaining this.

    Peptide
    Desmopressin
    Outcome
    IncreaseSodium balance versus AVP
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Comparator
    AVP-treated animals
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    The difference in sodium balance observed when DDAVP- and AVP-treated animals were compared could not be attributed to differences in either magnitude of water retention or filtered load of sodium.
    4 context sentences
    Summary · context
    In DDAVP-treated animals, sodium balance remained constant and hyponatremia resulted from water retention alone.
    Summary · context
    In AVP-treated animals, a greater degree of hyponatremia was observed and resulted from combined positive water balance and negative sodium balance.
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.
    Summary · context
    To determine if a decrease in the hydrosmotic effect of vasopressin occurred, urinary osmolality, flow rate, and free water reabsorption were measured sequentially in vasopressin-treated and control animals (receiving 0.22% NaCl alone).
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rats receiving hypotonic fluid, hyponatremia was less pronounced with DDAVP than with AVP.

    In plain wordsIn rats receiving hypotonic fluid, DDAVP produced less severe low blood sodium than AVP.

    Peptide
    Desmopressin
    Outcome
    DecreaseHyponatremia versus AVP
    Study

    ratn: not reported in source

    Conscious unrestrained rats receiving hypotonic fluid
    Comparator
    AVP-treated animals
    Outcome group
    Water And Electrolyte Balance · Kidney and urinary
    Studied dose
    0.112 ng/h · 4-6 daysAs given in this study (rat).

    Source sentences

    Summary
    In AVP-treated animals, a greater degree of hyponatremia was observed and resulted from combined positive water balance and negative sodium balance.
    2 context sentences
    Summary · context
    In DDAVP-treated animals, sodium balance remained constant and hyponatremia resulted from water retention alone.
    Summary · context
    We therefore infused vasopressin [either 1-desamino-8-D-arginine vasopressin (DDAVP) at 0.112 ng/h or arginine vasopressin (AVP) at 2.4 mU/h] and hypotonic fluid (0.22% NaCl at 3.1 ml/h) into conscious unrestrained rats for 4-6 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.